Amneal's specialty segment grows 23% in Q1 2026, driven by branded neurology and endocrinology portfolio expansion and margin improvement.

Oragenics licenses CardioDialysis technology for TBI treatment using preferred stock, targeting post-injury neuroinflammation through dual mechanisms.

Crinetics' paltusotine Q1 revenue reached $10.3M, doubling sequentially from Q4 2025 with 70% patient reimbursement rate achieved.

Zymeworks awaits zanidatamab approval decision on August 25, 2026, for first-line HER2-positive gastroesophageal adenocarcinoma, triggering a $250 million miles

Genmab's Q1 2026 royalty revenue rises 26% to $742M, driven by DARZALEX sales growth through Johnson & Johnson partnerships.

BridgeBio reports $180.6M in Attruby revenue for Q1 2026, while authorizing a $500M share buyback and advancing three pipeline...

PARP inhibitors reshaped ovarian cancer treatment, but with olaparib holding 38% market share and biomarker limits exposed, the next...

Oragenics licenses CardioDialysis Technology from Sigyn to combine with ONP-002 for treating traumatic brain injury inflammation.

Zymeworks' $250M milestone payment depends on Jazz's zanidatamab FDA decision scheduled for August 25, 2026, in HER2-positive gastroesophageal cancer.

Crinetics' Palsonify doubled sequential quarterly revenue to $10.3M in Q1, reaching 70% reimbursement coverage in acromegaly treatment.